MXPA04005307A - Clorhidrato de venlafaxina en forma de monohidrato y sus metodos de preparacion. - Google Patents

Clorhidrato de venlafaxina en forma de monohidrato y sus metodos de preparacion.

Info

Publication number
MXPA04005307A
MXPA04005307A MXPA04005307A MXPA04005307A MXPA04005307A MX PA04005307 A MXPA04005307 A MX PA04005307A MX PA04005307 A MXPA04005307 A MX PA04005307A MX PA04005307 A MXPA04005307 A MX PA04005307A MX PA04005307 A MXPA04005307 A MX PA04005307A
Authority
MX
Mexico
Prior art keywords
preparation
methods
venlafaxine hydrochloride
hydrochloride monohydrate
monohydrate
Prior art date
Application number
MXPA04005307A
Other languages
English (en)
Inventor
Han Jun
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA04005307A publication Critical patent/MXPA04005307A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a una forma polimorfica cristalina novedosa de clorhidrato de venlafaxina la cual existe en la forma hidratada (por ejemplo, como un monohidrato), a metodos para la preparacion del mismo, y a su uso.
MXPA04005307A 2001-12-05 2002-12-03 Clorhidrato de venlafaxina en forma de monohidrato y sus metodos de preparacion. MXPA04005307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33582301P 2001-12-05 2001-12-05
PCT/US2002/038581 WO2003050076A1 (en) 2001-12-05 2002-12-03 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof

Publications (1)

Publication Number Publication Date
MXPA04005307A true MXPA04005307A (es) 2004-09-13

Family

ID=23313363

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005307A MXPA04005307A (es) 2001-12-05 2002-12-03 Clorhidrato de venlafaxina en forma de monohidrato y sus metodos de preparacion.

Country Status (20)

Country Link
US (2) US20030114536A1 (es)
EP (1) EP1451146A1 (es)
JP (1) JP2005511737A (es)
KR (1) KR20050044711A (es)
CN (1) CN1599715A (es)
AR (1) AR037636A1 (es)
AU (1) AU2002366574A1 (es)
BR (1) BR0214696A (es)
CA (1) CA2467614A1 (es)
CO (1) CO5580817A2 (es)
EC (1) ECSP045134A (es)
HU (1) HUP0402553A2 (es)
MX (1) MXPA04005307A (es)
NO (1) NO20042810L (es)
PL (1) PL370559A1 (es)
RU (1) RU2004120273A (es)
TW (1) TW200300669A (es)
UA (1) UA77234C2 (es)
WO (1) WO2003050076A1 (es)
ZA (1) ZA200405245B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002348266A1 (en) * 2001-12-05 2003-06-23 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
KR20070045278A (ko) * 2004-07-22 2007-05-02 와이어쓰 신경계 질환 및 장애의 치료 방법
MX2007000853A (es) * 2004-07-22 2007-03-26 Wyeth Corp Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso.
US20060020014A1 (en) * 2004-07-22 2006-01-26 Wyeth Method for treating nervous system disorders and conditions
EP1824815A2 (en) * 2005-10-19 2007-08-29 Teva Pharmaceutical Industries Ltd. Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride
CA2655061A1 (en) 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
DK2792662T3 (da) 2007-05-01 2016-07-25 Concert Pharmaceuticals Inc Morphinanforbindelser
US20120083487A1 (en) * 2008-10-30 2012-04-05 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury
EP3344273B1 (en) * 2015-08-31 2019-12-25 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1153603B1 (en) * 1993-06-28 2006-10-18 Wyeth New treatments using phenethylamine derivatives
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
CZ20031298A3 (cs) * 2000-10-19 2003-10-15 Teva Pharmaceutical Industries Ltd. Způsob přípravy krystalické báze venlafaxinu a nových polymorfů hydrochloridu venlafaxinu
US6906087B2 (en) * 2000-10-31 2005-06-14 Ciba Specialty Chemicals Corpation Crystalline forms of venlafaxine hydrochloride
AU2001235970A1 (en) * 2000-12-07 2002-06-18 Dr. Reddy's Research Foundation Novel crystalline polymorphic forms of venlafaxine hydrochloride and a process for their preparation

Also Published As

Publication number Publication date
CA2467614A1 (en) 2003-06-19
AR037636A1 (es) 2004-11-17
PL370559A1 (en) 2005-05-30
NO20042810L (no) 2004-07-02
JP2005511737A (ja) 2005-04-28
ZA200405245B (en) 2007-01-31
HUP0402553A2 (hu) 2005-03-29
BR0214696A (pt) 2004-11-03
CO5580817A2 (es) 2005-11-30
AU2002366574A1 (en) 2003-06-23
RU2004120273A (ru) 2005-03-27
TW200300669A (en) 2003-06-16
UA77234C2 (en) 2006-11-15
EP1451146A1 (en) 2004-09-01
WO2003050076A1 (en) 2003-06-19
ECSP045134A (es) 2004-07-23
CN1599715A (zh) 2005-03-23
KR20050044711A (ko) 2005-05-12
US20030114536A1 (en) 2003-06-19
US20050272822A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
IL166710A0 (en) Process for the preparation of 4-ÄÄ4-ÄÄ-(2-cyanoethenyl)2,6-dimethylphenylÜaminoÜ-2-pyrimidinylÜaminoÜbenzonitrile
HUP0402269A3 (en) Methods for preparing o-desmethylvenlafaxine
EP1438074A4 (en) ADJUVANT COMPOSITIONS
RS20130524A3 (en) PROCEDURE FOR OBTAINING AMINO CROTONYL UNITS
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
IL188834A0 (en) Novel vaccine composition
TW200716512A (en) Processes for preparing cinacalcet hydrochloride crystal form I
AP1830A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
HUE037069T2 (hu) Eljárás nagy tisztaságú 2,4'-metiléndifenildiizocianát elõállítására
HUP0500540A3 (en) Extended release compositions comprising as active compound venlafaxine hydrochloride
TW200640861A (en) Amorphous lercanidipine hydrochloride
HK1087695A1 (en) Process for the preparation of n-substituted 2-cyanopyrrolidines n- 2-
HUP0303942A3 (en) Novel vaccine composition
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
MXPA04005307A (es) Clorhidrato de venlafaxina en forma de monohidrato y sus metodos de preparacion.
EP1552826A4 (en) AMINO ACID COMPOSITIONS TO IMPROVE CENTRAL FUNCTIONS
MXPA04005305A (es) Nuevo polimorfo cristalino de clorhidrato de venlafaxina y metodos para preparacion del mismo.
HUP0600231A2 (en) Novel process for the preparation of 2h-chromenes
IL160314A0 (en) Processes for the production of alpha-difluoromethyl ornithine (dfmo)
HUP0302313A3 (en) Co-retarding agents for preparing purified brine
WO2004024681A3 (fr) NOUVEAUX COMPOSES COMPRENANT UN GROUPEMENT THIOCARBONYLSULFANYLE UTILES POUR LA SYNTHESE DE COMPOSES α-PERFLUOROALKYLAMINES PAR VOIE RADICALAIRE
SI2181982T1 (sl) Postopek za pripravo venlafaksin hidroklorida oblike I
HUP0302199A3 (en) Retarding agents for preparing purified brine
AU2002337634A1 (en) Process for the preparation of bupropion hydrochloride
HUP0301982D0 (en) Process for the preparation of high purity d-(17alpha)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime